Cipla announced that it has received final approval for its Lanreotide injection, from the United States Food and Drug Administration (US FDA).  The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.  Lanreotide injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL single-dose pre-filled syringes. It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

Umang Vohra, MD and Global CEO, Cipla said, “We are pleased to receive the final approval for Lanreotide injection from the USFDA. Enabling access to high-quality treatments is core to our purpose of “Caring for Life”. This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs.”

The active ingredient, route of administration and strengths are the same as Somatuline Depot, from Ipsen Biopharmaceuticals Inc. According to IQVIA, Somatuline Depot had US sales of approximately US $ 867M for the 12-month period ending October 2021.